Amanta Healthcare Limited, a leading Ahmedabad-based pharmaceutical company specializing in sterile liquid products and medical devices, has launched its highly anticipated Initial Public Offering (IPO). The Rs 126 crore issue opened for subscription on Monday, September 1, 2025, and will remain open until Wednesday, September 3, 2025. With a price band fixed at Rs 120–126 per share and a Grey Market Premium (GMP) hovering around 22%, the IPO has already drawn significant attention from investors across the country.
The IPO is an entirely fresh issue of 1 crore equity shares, which means that all proceeds raised will go directly to the company to fuel its expansion plans, rather than offering an exit route for existing shareholders. The company’s shares are scheduled to list on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on September 8, 2025.
A Growing Force in the Pharma Sector
Founded with a vision to deliver high-quality healthcare products, Amanta Healthcare has carved a strong niche in the sterile liquid pharmaceutical segment. The company’s product portfolio includes sterile injectable products, intravenous (IV) fluids, eye drops, and a wide range of medical devices. By focusing on cutting-edge manufacturing technologies and stringent quality control, Amanta has successfully established itself as a trusted name among hospitals, healthcare professionals, and patients in India and several international markets.
Amanta operates state-of-the-art manufacturing facilities in Gujarat, equipped with advanced technology that meets global regulatory standards. Over the years, the company has expanded its export footprint to more than 20 countries, strengthening its position as a global healthcare solutions provider.
The proceeds from the IPO will primarily be utilized for capacity expansion, working capital requirements, R&D investments, and general corporate purposes. With increasing demand for sterile pharmaceutical products and medical devices both in India and globally, Amanta aims to strengthen its manufacturing capabilities and expand into new product categories.
Investor Sentiment and GMP Buzz
Ahead of the public issue, market analysts have noted strong investor sentiment, bolstered by the company’s growth track record and favorable industry outlook. The IPO’s Grey Market Premium (GMP) has been reported at around 22%, suggesting healthy listing gains for investors if market conditions remain supportive.
Industry experts believe that Amanta Healthcare’s presence in the high-demand sterile segment, coupled with its proven export potential, makes the IPO attractive. However, they also caution investors to consider sector-specific risks such as regulatory challenges, pricing pressures, and competitive intensity before making their decisions.
Industry Outlook
India’s pharmaceutical industry, often termed the “pharmacy of the world,” is poised for sustained growth, driven by rising healthcare awareness, expanding access to medical facilities, and increasing global demand for affordable and high-quality medicines. The sterile injectable and IV fluid markets, where Amanta holds significant expertise, are witnessing robust demand due to the growing prevalence of lifestyle diseases, surgical procedures, and emergency care requirements.
In addition, the government’s focus on healthcare infrastructure development and incentives for pharmaceutical exports provide a favorable policy backdrop for companies like Amanta Healthcare.
Management Commentary
Speaking on the launch of the IPO, Mr. [Name], Managing Director of Amanta Healthcare, said:
“The launch of our IPO is a significant milestone in Amanta Healthcare’s journey. Over the years, we have built a strong foundation in the sterile pharmaceutical space, supported by world-class infrastructure, innovation-driven R&D, and a commitment to delivering safe and effective products. With this IPO, we aim to accelerate our growth, expand our manufacturing capabilities, and strengthen our presence in domestic and global markets. We are confident that our investors will benefit from our vision for long-term sustainable growth.”
Should You Bid?
Market analysts suggest that the Amanta Healthcare IPO presents an opportunity for investors seeking exposure to a high-growth pharmaceutical segment. The company’s focus on sterile products, consistent financial performance, and global expansion plans position it favorably among peers. The positive GMP trend further adds to the appeal for investors looking for listing gains.
However, like all IPO investments, it is advisable for retail investors to carefully evaluate the company’s fundamentals, peer valuations, and long-term prospects before making a final decision. Experts recommend considering one’s own risk appetite, investment horizon, and portfolio diversification goals.
The Amanta Healthcare IPO has opened at a time when India’s pharmaceutical sector is riding a strong growth wave. With a robust product portfolio, international presence, and a clear strategy for capacity expansion, the company is well-positioned to capitalize on rising healthcare demand. Backed by encouraging GMP trends and positive market sentiment, the IPO is expected to generate strong interest from institutional as well as retail investors.
The subscription window remains open until September 3, 2025, with the much-awaited listing scheduled for September 8, 2025. For investors, the coming days will be crucial in deciding whether to participate in one of the most talked-about pharma IPOs of the year.
